Lataro (representing the active substance Lurasidone) is applied across domains where additional symptomatic support is needed for managing conditions characterized by periods of heightened symptoms and involving episodic or fluctuating manifestations. The medicine is relevant in contexts involving heightened systemic burden.

Lataro is commonly used to help with symptoms linked to two main psychiatric areas: schizophrenia in adults and adolescents, and depressive episodes associated with Bipolar I Disorder. These conditions are associated with symptoms that create noticeable physiological strain and may become temporarily overwhelming.

Lataro may assist with managing symptom clusters that become more disruptive during flare-ups. This supportive relief generally helps ease the overall symptom load and supports patients during episodes of heightened discomfort. The benefit provided is maintaining a sense of stability during phases of increased distress.

“This supportive approach may assist with helping patients cope more steadily with symptom fluctuations in contexts involving heightened systemic burden.”

Quick Fact: May assist with managing Symptoms that Interfere with Daily Functioning.

Official Eligibility and Contraindications

Lataro (Lurasidone) use is determined by specific rules outlined in official regulatory labeling, including age and concurrent medical conditions.

Classification	Eligibility Status (As per Labeling)
Populations Allowed	Adults with Schizophrenia or Bipolar I Depression. Adolescents (13–17 years) with Schizophrenia. Pediatric patients (10–17 years) with Bipolar I Depression.
Absolute Contraindications	Patients with a known hypersensitivity to the drug. Patients concurrently taking strong CYP3A4 inhibitors (e.g., ketoconazole) or strong CYP3A4 inducers (e.g., rifampin, St. John’s wort).

---

Condition and Age-Related Restrictions

Eligibility is conditional for certain patient groups:

• Organ Impairment: Patients with moderate or severe hepatic impairment or moderate or severe renal impairment have conditional eligibility and may be subject to officially defined maximum dose limits.
• Pediatric Use: Use is not established in children under 13 years for Schizophrenia or under 10 years for Bipolar I Depression.
• Geriatric Exclusion: The medicine is not approved for use in elderly patients with dementia-related psychosis.
• Pregnancy/Lactation: Use during pregnancy is permitted only if the potential benefit justifies the potential risk. Breastfeeding is not recommended.

Interactions with other medicines and products

Lataro is involved in significant pharmacokinetic interactions due to its dual activity as a substrate and inhibitor of cytochrome P450 3A4 (CYP3A4) and the efflux transporter P-glycoprotein (P-gp).

Interaction Classifications and Restrictions

Classification	Interacting Category / Specific Drug
Contraindicated	Strong CYP3A4 Inducers (e.g., rifampicin, carbamazepine, phenytoin, phenobarbital, St. John's Wort).
Dose Adjustment Required	Strong CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, saquinavir).
Use with Caution	P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, verapamil, quinidine).

Co-administration with strong CYP3A4 inducers is contraindicated because it leads to a marked decrease in Lataro's plasma concentrations, potentially resulting in a loss of therapeutic effect. Conversely, co-administration with strong CYP3A4 inhibitors significantly increases Lataro exposure, necessitating a dose reduction of Lataro to manage risk.

Lataro also acts as an inhibitor of CYP3A4 and P-gp. Therefore, co-administration with medicinal products that are sensitive substrates of these enzymes or transporters (such as digoxin or certain statins) may lead to an increase in the plasma concentrations of the co-administered drug. Monitoring and dose adjustments for the interacting medicine are required in these circumstances, based on official regulatory guidelines.

Lataro's Mechanism of Action

Lataro is a molecule that acts by engaging specific signaling pathways in the eye, which modulates the rate of internal fluid drainage. Its actions influence core mechanisms of fluid homeostasis, resulting in the modulation of intraocular fluid pressure. The action is segmented into two primary mechanistic domains: Receptor Activation and Outflow Modulation.

---

Prostaglandin Receptor Engagement

Lataro is an agonist that selectively binds to and activates the Prostaglandin F (FP) Receptor found in the eye's ciliary muscle and surrounding structures. This Receptor Activation initiates a cellular signaling cascade, affecting systems where specific lipid-derived mediators dominate, which leads directly to the mechanism of Extracellular Matrix Remodeling.

---

Uveoscleral Outflow Modulation

The cellular changes resulting from receptor binding include the increased production of matrix metalloproteinases (MMPs), which modify the structural integrity of the extracellular matrix. This Tissue Remodeling reduces resistance and increases permeability within the uveoscleral outflow pathway, increasing the rate of aqueous humor (eye fluid) drainage, which is the mechanism that results in a decrease in intraocular fluid pressure.

Administration Guidelines for Lataro

Lataro is a prescription medication containing the active substance Lurasidone, which is administered exclusively via the oral route as a tablet. The entire prescribed dose must be taken once daily.

---

Mandatory Administration Conditions

To ensure proper absorption, Lataro tablets must be taken with food; specifically, the medication should be consumed with a meal containing at least 350 calories. The tablets are designed to be swallowed whole and should not be crushed, chewed, or divided before intake.

---

Standard Dosing and Frequency

Lataro is used for both acute and maintenance treatment, and specific dosing ranges are established for its use.

Indication	Standard Daily Dosing Range	Starting Dose (Typical)
Schizophrenia (Adult)	40 mg to 120 mg	40 mg once daily
Bipolar Depression (Adult)	20 mg to 120 mg	20 mg once daily

---

Adjustments in Specific Populations

Dose modifications are utilized for patients with reduced organ function. For individuals with moderate-to-severe hepatic or renal impairment, the maximum recommended daily dose is restricted to 40 mg. Furthermore, specific maximum doses are defined for pediatric patients; for example, the dose cap for adolescents (ages 10-17) using Lataro for bipolar depression is 80 mg per day.

Research Evidence / Overview of Studies for Lataro

---

Evidence for Use in Primary Open-Angle Glaucoma ( POAG)

The evidence base for Lataro in POAG primarily relies on Randomized Controlled Trials ( RCTs), which are the main type of study regulators rely upon. These trials, often compared to other agents like Timolol, monitored the measured patterns of Intraocular Pressure ( IOP) over time in adults with the condition. Findings described measured IOP changes in observed patient groups during short-term study periods, typically lasting three to twelve months for initial study assessment. Some extension studies have examined whether these IOP changes persisted over treatment durations of up to two years or more. However, definitive long-term outcomes, such as the preservation of visual field function over many decades, often rely on extrapolation from these IOP measurements or on less controlled observational studies.

Evidence for Use in Ocular Hypertension ( OHT) and Adjunctive Therapy

Lataro was evaluated in studies involving patients with Ocular Hypertension ( OHT), which focused on short-term IOP changes and whether the measured IOP fell into a target range considered desirable by the researchers. The research contributed to the evidence landscape for OHT management, but many studies concentrate on IOP as a surrogate marker, and long-term studies tracking the definitive outcome of OHT progression to glaucoma remain limited.

Lataro was also examined as an add-on treatment for patients whose IOP was inadequately controlled by a single medication, based on study protocols. Studies monitored the additional measured IOP change observed when Lataro was introduced in combination regimens. Data are still emerging concerning the comprehensive, long-term impact and durability of these complex, two-drug regimens, as follow-up durations were often limited in the initial RCTs.

Evidence in Special Populations and Research Gaps

Lataro was evaluated in studies that included the older adult (geriatric) population, and the reported IOP change patterns were generally similar to those in younger adult cohorts. In contrast, evidence is limited for the pediatric population (children under 18 years of age), as data for the relationship of age to the measured IOP changes in this younger population remain insufficient.

Research gaps exist, as follow-up durations were limited in many core trials, meaning effects on complex outcomes like preserving the visual field are still uncertain. Evidence quality varies across studies, especially regarding long-term studies comparing Lataro to all available treatment options. Research is ongoing to better understand these long-term patterns.

Common questions about Lataro (FAQ)

Q: What is Lataro used for?

A: Lataro is indicated for the treatment of [Condition A] and as an adjunct therapy for [Condition B], as described in the official product labeling. Its use is based on regulatory approval for these specific conditions.

Q: Can I stop taking Lataro if I feel better?

A: It is generally advised not to abruptly stop taking any prescription medication unless specifically instructed by a healthcare provider. Stopping treatment suddenly may lead to a recurrence of symptoms or other effects. Always consult your doctor before making any changes to your treatment plan.

Q: What should I do if I miss a dose of Lataro?

A: Specific instructions for a missed dose are usually found in the patient information leaflet or provided by your prescribing doctor. In general, if you realize you missed a dose, consult the specific directions for Lataro, which typically advise either taking the missed dose as soon as you remember (if close to the usual time) or skipping the missed dose and returning to your regular schedule. Do not take two doses at once.

Q: Can Lataro be taken with alcohol?

A: The combination of Lataro and alcohol may potentially lead to increased central nervous system (CNS) side effects, such as drowsiness or dizziness. It is recommended to discuss alcohol consumption with your healthcare provider to understand the risk based on your individual health profile and dosage.

Storage and Packaging Requirements

Lataro must be stored at a regulated temperature of 25°C (77°F), which is defined as controlled room temperature. Brief temperature fluctuations are permitted between 15°C and 30°C (59°F and 86°F) to maintain the drug’s stability and potency.

The medication must be kept in its original container and the bottle must be stored tightly closed to protect the contents.

Child-Safety and Disposal

Official labeling requires that Lataro be stored out of the reach of children to prevent accidental ingestion.

Regulatory documents do not contain product-specific instructions for the disposal of Lataro, such as recommending the tablets be flushed. Therefore, disposal of unused or expired medicine must comply with general local, state, and federal regulatory requirements for pharmaceutical waste.